Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, which is UK’s third-largest health insurer behind Bupa and Axa, is to offer ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...